Myelodysplastic/Myeloproliferative Neoplasm Clinical Trials
35 clinical trials for Myelodysplastic/Myeloproliferative Neoplasm across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) — RECRUITING · PHASE2
- Personalized NK Cell Therapy in CBT — RECRUITING · PHASE2
- A Study of BGB-11417 in Participants With Myeloid Malignancies — RECRUITING · PHASE1
- Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant — RECRUITING · PHASE1
- Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS — RECRUITING · PHASE1
- Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. — RECRUITING · PHASE1
- Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia — RECRUITING · PHASE2
- A Telehealth Advance Care Planning Intervention — RECRUITING · NA
- Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms — RECRUITING · PHASE2
- Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia — RECRUITING · PHASE1
- Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy — RECRUITING · PHASE1
- Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes — RECRUITING · PHASE2
- Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant — ACTIVE_NOT_RECRUITING · PHASE2
- Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm — ACTIVE_NOT_RECRUITING · PHASE2
- Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms — ACTIVE_NOT_RECRUITING · PHASE1
- Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes — ACTIVE_NOT_RECRUITING · PHASE1
- Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
- A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies — COMPLETED · PHASE1
- Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms — COMPLETED
- Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation — TERMINATED · PHASE2
- Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia — NOT_YET_RECRUITING · PHASE2
- CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant — ACTIVE_NOT_RECRUITING · PHASE1
- Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia — COMPLETED · PHASE1
- A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms — TERMINATED · PHASE1
- Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia — COMPLETED · PHASE2
- Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm — COMPLETED · PHASE2
- PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome — COMPLETED · PHASE1
- EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia — TERMINATED · PHASE1
- Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia — OTHER · PHASE2
- Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant — WITHDRAWN · PHASE1
- Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant — COMPLETED · PHASE2
- Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies — COMPLETED · PHASE2
- Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies — COMPLETED · PHASE1
- WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome — COMPLETED · PHASE2
- Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer — COMPLETED · PHASE3
Refine this search